← Map · Health Care Equipment · S&P 500 · $34.9B · Last Jul 30 AMC
DXCM DEXCOM INC
Yes — next layer showed up on the call
What they are doing
Dexcom sells CGM. The product is a glucose algorithm plus an app. On the Q2 call, CEO Jake Leach said G7 15-day (new algorithm) should convert ~50% of the US base by year-end. Revenue $1.31B (+11%). CGM Type 2 (non-insulin): 16.4% +14C improvement, 0.9% vs control, + extra hours in range. That is a CGM outcome — do not double-count as an LLM. What the call added vs the 10-K: Stelo relaunch with “AI-driven insights.” Smart Basal pilot (optimal basal in ~3 weeks vs typical 1). Tempo FDA pilot to screen prediabetes.
Why the score
- Reach 3 not 4: sensing + app insights + basal dosing. Nutrition is thin.
- Weight 4 not 5: algorithm is the offer vs a bot. Weight 5 = Smart Basal / Tempo at scale.
- Proof 4 not 5: CGM Type 2 is a sensor KPI. Smart Basal 3-vs-1 is the right type, still a pilot.
What would move it next quarter: Smart Basal leaving pilot with a number, or % of users on AI insights that change behavior.
Open these first
Evidence
we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability. • Our products may not achieve or maintain market acceptance. • If we, our suppliers, or our distributors fail to comply regivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized
regivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025. In August 2 on arrangements in North America and several international markets that allow distributors to sell our products. Future Developm
Leach on CGM Type 2, Stelo, Smart Basal, Investor Day
Road to 100, 5-year plan, Tempo — the strategy deck